The Impact of Alendronate on Bone Mineral Density of Osteoporotic Patients

  • Hamidreza Aghaei-Meybodi Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Negin Rashidi Mail Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Mahdi Montazeri Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Abbasali Keshtkar Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Patricia Khashayar Osteoporosis Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Keywords:
Alendronate, Bone density, Osteoporosis

Abstract

The present study assessed the real life therapeutic effects of weekly doses of alendronate in treating a group of osteoporotic patients in Iran. The present historical cohort was conducted on patients who had undergone two or more bone mineral densitometry within an interval of 1.5-2 years in Shariati Hospital bone mineral density department between 2002 and 2010.patients were asked by phone about consumption of alendronate. The mean increase in the BMD values at different sites was calculated. There was a significant increase in the body mass index (BMI) values of both the individuals taking alendronate and the control group (P<0.001). Taking the weekly dosage of the drug was associated with a 7.67% increase in the BMD values at the femoral neck, 8.68% at the total hip, and 3.17% at the lumbar spine. Moreover, our results showed a significant difference between the height decline in the two groups (alendronate taking: 0.7±2.4 vs. control: -0.7±2.6, P<0.001). Comparing the results of the present study with that of previous ones revealed the drug is beneficial in improving bone mineral density in Iranians; as well alendronate is more effective in Iranian postmenopausal women when compared with the Americans.

References

Nof.org. [Internet]. Washington (DC): prevalence report, National Osteoporosis Foundation. [updated 2002]. Available from http://old.nof.artsmithclients.com/advocacy/resources/prevalencereport.

Maalouf G, Gannagé-Yared MH, Ezzedine J, Larijani B, Badawi S, Rached A, Zakroui L, Masri B, Azar E, Saba E, Nammari R, Adib G,Abou Samra H, Alrawi Z, Salman S, El Muntasser K, Tarseen R, El Kharousi W, Al-Lamki M, Alothman AN, Almarzook N, El Dessouki M, Sulaimani R, Saleh J, Suhaili AR, Khan A, Delmas P, Seeman E.. Middle East and North Africa consensus on osteoporosis. J Musculoskelet Neuronal Interact 2007;7(2):131-43.

Larijani B, Resch H, Bonjour JP, Aghai Meybodi HR, Mohajery Tehrani MR. Osteoporosis in Iran, Overview and Management. Iranian J Publ Health 2007; suppl:1-13.

Cummings SR, Melton LJ . Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359(9319):1761-7.

NIH consensus statement. Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000;17(1):1-45.

NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95.

Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Met 2010;95(4):1555-65.

Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. II. Metaanalysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23(4):508-16.

Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd. Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996;101(5):488-501.

.Chesnut CH 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multipledosages on bone mass and bone remodeling. Am J Med 1995;99(2):144-52.

Adami S, Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Saf 1996;14(3):158–70.

Simmons J, Zeitler P, Steelman J. Advances in the Diagnosis and Treatment of Osteoporosis. Adv Pediatr 2007;54:85–114.

Rizzoli R, Greenspan SL, Bone G 3rd, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC 2nd,Kaur A, Peverly CA, Orloff JJ. Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 2002;17(11):1988-96.

Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC,Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350(12):1189-99.

Procon.org [Internet]. Santa Monica: Comparison of Calcium Content in Select Foods [updated 2009 June 1]: available from http://milk.procon.org/view.resource.php?resourceID=000659.

Faulkner KG. Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 2000;15(2):183-7.

Riis BJ, Hansen MA, Jensen AM, Overgaard K, Christiansen C. Low bone mass and fast rate of bone loss at menopause: equal risk factors for future fracture: a 15- year follow-up study. Bone 1996;19(1):9-12.

Ammann P, Rizzoli R. Bone strength and its determinants. Osteoporos Int 2003;14 (Suppl 3):S13-8.

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18(2):141-50.

Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab 2000;85(2):720-6.

Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE;Fosamax Actonel Comparison Trial Investigators. Treatment with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized, doubleblind= study. J Bone Miner Res 2005;20(1):141-51.

Luckey M, Kagan R, Greenspan S, Bone H, Kiel RD, Simon J, Sackarowitz J, Palmisano J, Chen E, Petruschke RA, de Papp AE. Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause 2004;11(4):405-15.

Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B , Zhang G, Li F. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers= in postmenopausal Chinese women with osteoporosis. J Bone Miner Metab 2009;27(4):471-8.

Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280(24):2077-82.

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41.

How to Cite
1.
Aghaei-Meybodi H, Rashidi N, Montazeri M, Keshtkar A, Khashayar P. The Impact of Alendronate on Bone Mineral Density of Osteoporotic Patients. Acta Med Iran. 51(12):855-860.
Section
Articles